JPMorgan analyst Anupam Rama upgraded Dynavax Technologies to Overweight from Neutral and raised his price target for the shares to $27 from $25. While a Heplisav launch inflection in 2019 is widely expected, the company's SD-101 opportunity is being "vastly underappreciated" at current share levels, Rama tells investors in a research note. SD-101 has shown encouraging early signals of efficacy in both the melanoma and head and neck indications, the analyst contends. Rama points out that a Phase 2 melanoma update is expected next month at ASCO. He likes the stocks' reward/risk profile going into the readout. The analyst sees 30%-60% upside potential versus 0%-10% downside risk on the data.